<DOC>
	<DOCNO>NCT00397709</DOCNO>
	<brief_summary>The objective study compare compliance side effect short course treatment latent tuberculosis infection 3 month ( isoniazid plus rifampin ) group I , standard course 6 month ( isoniazid ) group II .Prospective , comparative , randomize open trial patient positive TST suitable criterion treatment , accordance guideline CDC , exclude HIV infection . 105 patient include . In Conclusion , short course isoniazid plus rifampin 3 month show well compliance low percentage abandonment course 6H . Tolerance similar two course .</brief_summary>
	<brief_title>Short-Course Isoniazid Rifampin Compared With Isoniazid Latent Tuberculosis Infection</brief_title>
	<detailed_description>Introduction : The objective study compare compliance side effect short course treatment latent tuberculosis infection 3 month standard course 6 month . Methods : Prospective , comparative , randomize open trial patient positive TST suitable criterion treatment , accordance guideline CDC , exclude HIV infection . group I assign isoniazid ( H ) dose 300 mg per day 6 month group II assign isoniazid dose 300 mg per day plus rifampin ( R ) ( 600 mg per day ) 3 month . The patient follow five year . Results : 105 patient include , 9 refuse treatment ; 45 patient include group I 51 patient group II . Both group comparable base level . The hepatotoxicity 44 % group 6H 29 % group 3HR ( p = 0,07 ) . The hepatotoxicity severe 6.7 % group 6H 5.8 % group 3HR ; oblige suspension treatment 4.4 % 1.9 % , respectively ( p =NS ) . The proportion patient complete study treatment 75.6 % patient group 6H , 90.2 % group 3HR ( p = 0,05 ) . Only case tuberculosis detect second month treatment 6H . Conclusion : In treatment latent tuberculosis infection , short course isoniazid plus rifampin 3 month show well compliance low percentage abandonment course 6H . Tolerance similar two course .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Latent Tuberculosis</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<criteria>patient positive TST suitable criterion treatment , accordance guideline CDC : HIV infection . Hepatopathy Previous treatment latent tuberculosis infection . Allergy drug .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>November 2006</verification_date>
	<keyword>Latent tuberculosis infection .</keyword>
	<keyword>Isoniazid .</keyword>
	<keyword>Rifampin .</keyword>
	<keyword>Clinical trial .</keyword>
	<keyword>treatment latent tuberculosis infection</keyword>
</DOC>